Cibc World Market Inc. Invests $2.64 Million in Revolution Medicines, Inc. $RVMD

Cibc World Market Inc. acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 14,093 shares of the company’s stock, valued at approximately $2,639,000.

Other large investors also recently modified their holdings of the company. Contravisory Investment Management Inc. bought a new stake in Revolution Medicines in the 2nd quarter worth approximately $32,000. Global Retirement Partners LLC grew its position in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after acquiring an additional 361 shares during the last quarter. Torren Management LLC bought a new position in Revolution Medicines during the fourth quarter valued at approximately $33,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines during the second quarter valued at approximately $37,000. Finally, Arax Advisory Partners purchased a new position in shares of Revolution Medicines during the fourth quarter worth approximately $38,000. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Price Performance

RVMD opened at $215.44 on Thursday. The stock’s 50 day simple moving average is $191.27 and its 200 day simple moving average is $147.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. Revolution Medicines, Inc. has a 1 year low of $35.64 and a 1 year high of $220.34. The firm has a market cap of $46.18 billion, a price-to-earnings ratio of -24.43 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company posted ($1.31) earnings per share. As a group, analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approval expands Revolution Medicines beyond clinical development and opens a potentially significant revenue opportunity in a cancer with substantial unmet treatment needs. The drug’s accelerated review and favorable efficacy profile reinforce investor confidence in the company’s RAS/MAPK-focused platform. Reuters FDA approval article
• Positive Sentiment: Management priced RASONQUE at approximately $39,800 per month, establishing a high-value commercial product and giving investors an initial benchmark for potential sales. RASONQUE pricing article
• Positive Sentiment: TD Cowen upgraded RVMD to “strong buy,” while other analysts have maintained bullish ratings and price targets above recent trading levels. Institutional ownership and reported purchases by some funds also provide supportive sentiment.
• Neutral Sentiment: The stock’s reaction has been relatively restrained despite the approval, likely because investors had anticipated the decision and RVMD already trades at an elevated valuation after a substantial run-up.
• Negative Sentiment: The $39,800 monthly list price could intensify scrutiny from insurers, policymakers and patients, potentially limiting access or slowing adoption. This pricing concern may be offsetting some of the enthusiasm surrounding the FDA decision. Pricing impact article
• Negative Sentiment: Insider Mark Goldsmith sold 80,000 shares for about $16.7 million, reducing his holdings by roughly 23%. Although one insider transaction is not necessarily a change in fundamentals, it can create a modest sentiment overhang after the stock’s sharp appreciation. Insider sale article

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $230.00 price objective on shares of Revolution Medicines in a report on Thursday, August 6th. Sanford C. Bernstein increased their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a report on Friday, August 21st. Needham & Company LLC lifted their target price on shares of Revolution Medicines from $236.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Guggenheim lifted their target price on shares of Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Piper Sandler boosted their price target on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $167.89.

Insider Transactions at Revolution Medicines

In related news, COO Margaret A. Horn sold 60,400 shares of Revolution Medicines stock in a transaction on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the transaction, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at $25,342,417.74. The trade was a 27.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the sale, the director owned 21,656 shares of the company’s stock, valued at $4,071,111.44. This represents a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 212,497 shares of company stock valued at $38,206,486. 7.60% of the stock is currently owned by insiders.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.